Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;185(3):671-673.
doi: 10.1111/bjd.20406. Epub 2021 Jun 14.

Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic

L Penso  1   2 , R Dray-Spira  1 , A Weill  1   3 , M Zureik  1   4 , E Sbidian  1   2   5   6
Affiliations

Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic

L Penso et al. Br J Dermatol. 2021 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Radar plot. (a) Number of healthcare users with psoriasis treated with biologics per month from 2015 to 2020. (b) Number of new biologic users per month from 2015 to 2020.
See this image and copyright information in PMC

References

    1. Yiu ZZN, Ashcroft DM, Evans I et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 2019; 180:329–37. - PMC - PubMed
    1. Dávila‐Seijo P, Dauden E, Descalzo MA et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol 2017; 137:313–21. - PubMed
    1. Lebwohl M, Rivera‐Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID‐19? J Am Acad Dermatol 2020; 82:1217–8. - PMC - PubMed
    1. EPI‐PHARE. Covid‐19: usage des médicaments de ville en France. Available at https://www.epi‐phare.fr/rapports‐detudes‐et‐publications/covid‐19‐usage... (last accessed 4 February 2021) (in French).
    1. Sbidian E, Mezzarobba M, Weill A et al. Persistence of treatment with biologics for patients with psoriasis: a real‐world analysis of 16 545 biologic‐naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol 2019; 180:86–93. - PubMed

Substances